Vasculitis Damage Index (VDI)
Vasculitis Damage Index for Systemic Vasculitis · Also known as: VDI, Vasculitis Permanent Organ Damage Score
The VDI is a clinician-assessed measure of permanent organ damage in patients with systemic vasculitis, including ANCA-associated vasculitis (AAV), polyarteritis nodosa, and other necrotising vasculitides. Introduced by Exley et al. (2003), VDI captures cumulative irreversible damage across organ systems, complementing disease activity measures (such as the Birmingham Vasculitis Activity Score). Systemic vasculitis is characterised by inflammation of blood vessel walls, leading to ischaemia and permanent tissue damage. VDI acknowledges that damage accrues over time and is largely irreversible, making it a prognostically important measure distinct from transient inflammatory activity.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
VDI is used in systemic vasculitis cohorts and clinical trials to assess cumulative damage. Perform VDI assessment at baseline to establish damage burden, then periodically (every 6–12 months) to track whether new organ damage develops—rising VDI indicates disease progression despite therapy. VDI is particularly valuable for: (1) long-term prognostic assessment (high baseline or rising VDI predicts mortality, end-stage renal disease, and disability); (2) evaluating therapy efficacy beyond activity reduction (goal is to prevent new damage, not just control inflammation); (3) research comparing long-term outcomes across treatment strategies (induction vs. maintenance therapy, conventional vs. biologic agents); (4) identifying patients at high risk for poor outcomes and requiring intensive monitoring; (5) shared decision-making regarding therapy intensity and long-term disease expectations. VDI is validated for ANCA-associated vasculitis, polyarteritis nodosa, and other systemic vasculitides; use disease-specific versions where available.
Strengths & limitations
- Captures irreversible damage distinct from transient activity; enables prognosis assessment independent of current inflammation.
- Multisystem assessment; captures organ damage across all major systems affected by vasculitis, from renal to neurologic to ENT.
- Predictive validity for long-term outcomes; high baseline or rising VDI predicts mortality, end-stage renal disease, work disability, and hospitalisation.
- Stable measure; VDI reflects cumulative history and is less volatile than activity scores, enabling precise tracking of disease progression.
- Clinically relevant; identifies patients with multiorgan damage requiring comprehensive support (nephrology, otolaryngology, pulmonology, neurology) and social services.
- Outcome measure for vasculitis trials; demonstrates whether therapy prevents new organ damage, a critical efficacy endpoint.
- Shared decision-making; discussions of baseline VDI and prognosis inform realistic expectations and intensity of therapy.
- Clinician-dependent assessment; requires expertise in multimodal evaluation (imaging, lab, functional testing) across organ systems; inter-rater variability possible.
- Binary scoring (0 or 1 per system) does not capture severity of damage within an organ; progression from stage 2 to stage 5 CKD scores identically as initial CKD onset.
- Does not differentiate activity-related vs. treatment-related vs. non-vasculitis-related damage; irreversible hearing loss may be from vasculitis, ototoxic drugs, or age-related.
- Lag time in damage manifestation; some damage (e.g., fibrosis, scars) develops months to years after inflammation; VDI may not capture all damage at time of assessment.
- Limited sensitivity to change in short-term trials; VDI accumulates slowly; trials lasting <12 months unlikely to detect rising VDI.
- Requires comprehensive assessment across multiple specialties; impractical in resource-limited settings without multidisciplinary vasculitis expertise.
- Does not reflect quality of life or functional impact; high VDI may underestimate patient suffering if damage is unilateral or compensated (e.g., unilateral hearing loss).
Frequently asked
What does a VDI of 2 mean?
A VDI of 2 indicates permanent damage in two organ systems attributed to vasculitis. Example: renal insufficiency + hearing loss = VDI 2. This reflects moderate cumulative disease burden with increased risk for further complications. Continue monitoring for new organ involvement.
Can VDI improve with treatment?
No. VDI reflects permanent, irreversible damage. Treatment cannot reverse established end-stage renal disease, hearing loss, or fibrosis. The goal of treatment is to prevent VDI from rising (i.e., prevent new organ damage), not to improve existing VDI. If a patient develops new organ involvement despite therapy, VDI rises.
What is the difference between VDI and a disease activity score like BVAS?
BVAS (Birmingham Vasculitis Activity Score) measures current, active inflammation; high BVAS indicates ongoing vasculitis requiring treatment escalation. VDI measures cumulative permanent damage; high VDI reflects disease history, not current activity. A patient in remission (low BVAS) may have high VDI from previous flares. Both are important: BVAS guides current therapy, VDI predicts long-term prognosis.
If my VDI is high but my BVAS is low, what does this mean?
High VDI with low BVAS indicates you are in remission (well-controlled disease) but carry permanent damage from previous flares. This is favourable; the goal is remission without additional damage accrual. Continue monitoring to ensure BVAS remains low; rising BVAS in this context warns of flare and risk of further damage.
Can VDI be used to diagnose vasculitis?
No. VDI measures damage only in patients with established vasculitis diagnosis. Diagnosis requires clinical features, serology (e.g., ANCA testing), imaging (angiography or biopsy), and multisystem assessment. VDI is a monitoring tool in diagnosed patients.
How often should VDI be assessed?
Baseline VDI at diagnosis establishes cumulative damage burden. Reassess every 6–12 months or at time of suspected new organ involvement. More frequent assessment is not necessary; VDI changes slowly. Annual assessment during maintenance therapy is adequate.
What if I develop new symptoms but my VDI hasn't changed?
New symptoms may reflect active inflammation (rising BVAS) rather than new permanent damage (rising VDI). For example, new haemoptysis indicates active pulmonary vasculitis but does not yet constitute VDI damage unless pulmonary fibrosis or loss of function develops. Clarify with imaging and spirometry whether new symptoms reflect reversible activity or permanent damage.
Does a high VDI mean my prognosis is poor?
High VDI indicates substantial cumulative damage and increased risk for further complications (progressive renal failure, progressive hearing loss, hospitalisation). However, if current BVAS is low (disease in remission), further damage may be prevented with continued therapy. Prognosis depends on both VDI (past damage) and current activity control.
Sources
- Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Pusey CD, Savage CO. Development and initial validation of the Vasculitis Damage Index (VDI) for systemic vasculitis. Arthritis & Rheumatism. 2003;48(7):2146-2157. link ↗
How to cite this page
ScholarGate. (2026, June 3). Vasculitis Damage Index for Systemic Vasculitis. ScholarGate. https://scholargate.app/en/rheumatology/vasculitis-damage-index
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Bath Ankylosing Spondylitis Disease Activity IndexRheumatology↔ compare
- Disease Activity Score 28Rheumatology↔ compare
- Routine Assessment of Patient Index Data 3Rheumatology↔ compare
- Systemic Lupus Erythematosus Disease Activity IndexRheumatology↔ compare